BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

MLA

Chu, Quincy, et al. “BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.” JTO Clinical and Research Reports, vol. 3, no. 11, Aug. 2022, p. 100400. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2022.100400.

APA

Chu, Q., Leighl, N. B., Surmont, V., van Herpen, C., Sibille, A., Markman, B., Clarke, S., Juergens, R. A., Rivera, M. A., Andelkovic, V., Rudin, C. M., Snow, S., Kim, D.-W., Sanatani, M., Lin, H., Sanghavi, K., Tannenbaum-Dvir, S., Basciano, P., Lathers, D., … Ready, N. (2022). BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO Clinical and Research Reports, 3(11), 100400. https://doi.org/10.1016/j.jtocrr.2022.100400

Chicago

Chu, Quincy, Natasha B Leighl, Veerle Surmont, Carla van Herpen, Anne Sibille, Ben Markman, Stephen Clarke, et al. 2022. “BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.” JTO Clinical and Research Reports 3 (11): 100400. doi:10.1016/j.jtocrr.2022.100400.